



Meeting Agenda

June 16-18, 2021

Day 1: Wednesday June 16, 2021

11:00 AM Opening Remarks

Suresh Ramalingam, MD
Hajian Fu, PhD

Keynote Speaker 1: Nadia Howadler, PhD
11:05 AM-11:30 AM
Presentation Title: TBD

Session 1 – Therapeutic Resistance
Moderator: Peter Ujhazy

11:45 AM	MET alterations are enriched in lung adenocarcinoma brain metastases and define a distinct molecular and transcriptomic subtype	Stabile/Hillman Cancer Ctr
----------	---------------------------------------------------------------------------------------------------------------------------------	-----------------------------------

11:55 AM MERTK activation drives EGFR-mutated non-small cell lung cancer resistant to osimertinib **Yan/Emory**

12:05 PM Brain metastasis and sanctuary osimertinib resistance are potentiated by RhoA in EGFR mutant lung cancer **Nguyen/Yale**

12:15 PM Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib **Chen/Emory**

12:25 PM Differential network targeting of ROS1 inhibitors reveals lorlatinib polypharmacology **Liao/Moffitt**

12:35 PM- **Panel Discussion**
1:00 PM

LUNCH 1:00 PM-1:30 PM

Keynote Speaker 2: Trudy Oliver, PhD
1:30 PM-1:55 PM
Presentation Title:TBD

Session 2 – KRAS, LKBI, and Related Pathways

Moderator: David Gerber

2:10 PM	Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non-small cell lung cancer	Crosson/UCLA
---------	---------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------

2:20 PM Revitalizing immune responsiveness of LKB1 mutant lung cancers through modulating the IAP-JAK-STING regulatory axis **Mo/Emory**

2:30 PM	Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS mutant lung cancer	Padhye/MDACC
---------	-----------------------------------------------------------------------------------------------------------------	---------------------

2021 National Lung Cancer SPORE Workshop Meeting Agenda June 16-18, 2021

2:40 PM	Dendritic cell in situ vaccination sensitizes Lkb1-deficient murine NSCLC to anti-PD-1 therapy	<i>Salehi-Rad/UCLA</i>
2:50 PM	Targeting bone morphogenic protein 6 as a therapeutic target for LKB1-inactivated lung cancer	<i>Gilbert-Ross/Emory</i>
3:00 PM	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells	<i>Li/UT Southwestern</i>
3:10 PM-3:35 PM	Panel Discussion	
	<i>BREAK 3:35 PM-3:50 PM</i>	

Session 3 – Novel Targets Moderator: Haian Fu

3:50 PM	Therapeutic targeting of PCDH7 in lung adenocarcinoma	<i>O'Donnell/UT Southwestern</i>
4:00 PM	LSD1 inhibition synergizes with immune checkpoint blockade in small cell lung cancer	<i>Hiatt/Fred Hutch</i>
4:10 PM	Tumor cell Intrinsic complement regulatory proteins promote tumor growth in a mouse model of NSCLC	<i>Kleczko/Univ of Colorado</i>
4:20 PM	KDM2A maintains redox homeostasis to suppress ferroptosis and drive lung cancer metastasis	<i>K Patel/Yale</i>
4:30 PM	MicroRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an Interleukin-2 mediated anti-tumor CD8+ cytotoxic T-cell response.	<i>Kundu/MDACC</i>
4:40 PM-5:05 PM	Panel Discussion	
	ADJOURN	

2021 National Lung Cancer SPORE Workshop Meeting Agenda June 16-18, 2021

Day 2: Thursday June 17, 2021

Keynote Speaker: Robert Winn, MD
11:00 AM- 11:25 AM
Presentation Title: TBD

Session 4 – Immunotherapy
Moderator: Tina Cascone

11:40 AM	Understanding how IL-2 cytokine synergizes with PD-1 directed immunotherapy during chronic viral infection	<i>Hashimoto/ Emory</i>
11:50 AM	Early and sustained proliferative CD8 responses after immune therapy in cancer patients	<i>Nasti/Emory</i>
12:00 PM	Associations between antibiotic exposure and circulating immune biomarkers in patients receiving immune checkpoint inhibitor therapy	<i>Von Itzstein/UT Southwestern</i>
12:10 PM	Small molecule Bax activator enhances immunotherapy against lung cancer	<i>Deng/Emory</i>
12:20 PM	Dual CPI therapy in advanced NSCLC reveals B cell profiles predictive of extrafollicular activation and robust anti-tumor development	<i>Cashman/Emory</i>
12:30 PM	Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors	<i>Gerber/UT Southwestern</i>
12:40 PM	Effect of concomitant antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: analysis of the national veterans health administration database	<i>Stokes/Emory</i>
12:50 PM	Resistance to combination anti-PD-1/-CTLA-4 therapy is reversed by Ly6C blockade-mediated reprogramming of tumor-infiltrating monocytes into dendritic cells	<i>Rodriguez/MDACC</i>
1:00 PM-1:25 PM	Panel Discussion LUNCH 1:25 PM-1:55 PM	

Session 5 – EGFR and Other Signaling Pathways
Moderator: Katherine Politi

1:55 PM	Role of the KEAP1 pathway in modulating sensitivity to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma	<i>Foggetti/Yale</i>
2:05 PM	Inhibition of 3-phosphoinositide-dependent kinase 1 (PDK1) overcomes osimertinib resistance in EGFR mutant NSCLC	<i>Meraz/UT MDACC</i>

2021 National Lung Cancer SPORE Workshop

Meeting Agenda

June 16-18, 2021

2:10 PM	Structure-based classification predicts drug response in EGFR mutant NSCLC	Robichaux/MDACC
2:20 PM	Loss of function mutation in histone lysine methyltransferase SETD1B gene predispose to acquired resistance of osimertinib in an EGFR mutant lung cancer patient-derived xenograft (PDX)	Fang/MDACC
2:30 PM- 2:55 PM	Panel Discussion	
	BREAK 2:55 PM-3:10 PM	

Session 6 – Molecular Profiling and Biomarkers

Moderator: David MacPherson

3:10 PM	LKB1, KEAP1 and ATM loss drive sensitivity to DNA-damage repair inhibitors in KRAS-mutant NSCLC	Galan-Cobo/MDACC
3:20 PM	Machine learning-based analyses of exosomal spectroscopic signatures in the detection of early lung cancer metastatic phenotypes	Paul/UCLA
3:30 PM	Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing	Sinjab/MDACC
3:40 PM	Immune editing and escape in non-small cell lung cancer tumors with human leukocyte antigen supertype B44 motif neoepitopes	Garon/David Geffen
3:50 PM- 4:15 PM	Panel Discussion	

Session 7 – COVID-19, Premalignancy, Risk Stratification, and Chemoprevention, Patient Related/Advocate Issues, and Clinical Trials and Cooperative Group Efforts

Moderator: Suresh Ramalingam

4:15 PM	Covid 19 and Lung Cancer	Hirsch/Mt Sinai
4:25 PM	Non-small cell lung tumor-derived biomarkers distinguish benign from malignant pulmonary nodules	Lastwika/Fred Hutch
4:35 PM	Lung cancer screening mortality benefits are potentially increased with inclusion of more African American/Black participants	Prosper/UCLA
4:45 PM	Sustaining and accelerating research in oncogene-driven rare lung cancers: Lessons from the 2020 ROS1der Research Roundtable	Freeman-Daily/Univ of Colorado
4:55 PM	Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced non-small cell lung cancer (NSCLC)	Liu/UCLA



EMORY
WINSHIP
CANCER
INSTITUTE

National Cancer Institute-Designated
Comprehensive Cancer Center

2021 National Lung Cancer SPORE Workshop
Meeting Agenda
June 16-18, 2021

5:05 PM-
5:30 PM

Panel Discussion

ADJOURN

2021 National Lung Cancer SPORE Workshop Meeting Agenda June 16-18, 2021

Day 3: Friday June 18, 2021

Keynote Speaker: Christine Lovly, MD, PhD
11:00 AM-11:25 AM
Presentation Title: TBD

Session 8 – Small Cell Lung Cancer Moderator: Lauren Byers

11:40 AM	Evasion of innate immunity contributes to small cell lung cancer progression and metastasis	<i>Akbay/UT Southwestern</i>
11:50 AM	Metabolic profiling and inhibitor vulnerabilities in small cell lung cancer	<i>Cargill/ UT MDACC</i>
12:00 PM	Evaluation of AXL inhibitors as novel therapeutic agents in small cell lung cancer	<i>Ramkumar/UT MDACC</i>
12:10 PM	Autoantibody-based early detection of small-cell lung cancer by immunoimaging	<i>Kunihiro/Fred Hutch</i>
12:20 PM- 12:45 PM	Panel Discussion	
	ADJOURN	